Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China

June 14, 2020 updated by: Wen-hong Zhang, Huashan Hospital
The purpose of the study is to collect health-seeking pathways, sociodemographic characteristics and symptoms of 400 newly diagnosed patients with bacteriologically confirmed pulmonary tuberculosis(TB).

Study Overview

Detailed Description

This research is a retrospective, multicenter, case-control study. The purpose of this study is to collect and assess health-seeking pathways, sociodemographic characteristics and symptoms of 400 newly diagnosed patients with bacteriologically confirmed pulmonary tuberculosis(TB).

According to inclusion criteria and exclusion criteria, a total of 400 participants with bacteriologically confirmed TB will be recruited and acquired their health-seeking pathways in different clinical institutions of pulmonary tuberculosis. Totally, 20 TB-designated medical institutions will be conducted in depth, covering the eastern region (7), the central region (8) and the western region (5), each hospital will enroll 20 eligible patients on the basis of convenience.

The cohorts are divided into delayed diagnosis and undelayed diagnosis. The former is defined if The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert. By offline or online interview, we aim to collect basic sociodemographic characteristics, symptoms, health-seeking pathway, including: hospital name, the date of each visit, laboratory tests and radiology evaluation results, diagnosis, treatment, medical and transportation costs. Then list the hospitals of previous consultations and trace their classification through the official website of the Health and Medical Commission. Determine whether these hospital are designated institution based on the CDC's publicity. Consult the laboratory facilities by phone.

The primary objective is to gain the median time of pulmonary tuberculosis diagnosis confirmed and the correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis.

The secondary objective is to gain the bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert; the correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis; the sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay; The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Anhui
      • Hefei, Anhui, China
        • Anhui Province Hospital
    • Guangdong
      • Shenzhen, Guangdong, China
        • The Third People's Hospital of Shenzhen
    • Guangxi
      • Beihai, Guangxi, China
        • Beihai Tuberculosis Hospital
    • Guizhou
      • Guiyang, Guizhou, China
        • Guiyang Public Health Clinical Center
    • Hei Longjiang
      • Daqing, Hei Longjiang, China
        • The 2th Hospital of Daqing
    • Henan
      • Zhengzhou, Henan, China
        • Henan Province Infectious Diseases Hospital
    • Hubei
      • Wuhan, Hubei, China
        • Wuhan Medical Treatment Center
    • Hunan
      • Huaihua, Hunan, China
        • The First People's Hospital of Huaihua
    • Jiangsu
      • Taicang, Jiangsu, China
        • The First People's Hospital of Taicang
      • Xuzhou, Jiangsu, China
        • Xuzhou Infectious Diseases Hospital Huimei Liu
    • Jiangxi
      • Nanchang, Jiangxi, China
        • Jiangxi Province Chest Hospital
    • Jilin
      • Changchun, Jilin, China
        • Changchun Infectious Diseases Hospital
    • Shandong
      • Jinan, Shandong, China
        • Shandong Province Chest hospital
    • Shanghai
      • Shanghai, Shanghai, China
        • Shanghai Public Health Clinical Center
      • Shanghai, Shanghai, China
        • 905th Hospital of PLA Navy
    • Shanxi
      • Xian, Shanxi, China
        • Xian Chest Hospital
    • Sichuan
      • Luzhou, Sichuan, China
        • Southwest Medical University Affiliated Hospital
    • Yunnan
      • Qiubei, Yunnan, China
        • Qiubei People's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Hangzhou Red Cross Hospital
      • Wenzhou, Zhejiang, China
        • Wenzhou Central Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

In the study, 400 patients with bacteriologically confirmed pulmonary tuberculosis(TB) were chose from 20 hospitals, each hospital select 20 patients according to the eligibility criteria randomly. These 20 TB-designated medical institutions are covering the eastern region (7), the central region (8) and the western region (5) among China.

Description

Inclusion Criteria:

  • Bacteriological positive: including positive AFB smear/ culture / molecular test;
  • Agree to accept this survey;

Exclusion Criteria:

  • HIV antibody positive and AIDS patients;
  • Combined with extrapulmonary TB;
  • Critically ill patients, and according to the judgment of the research physician, it is impossible to survive for more than 16 weeks;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
delayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
undelayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The median time of pulmonary tuberculosis diagnosis confirmed
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
Time from the date of patients' symptoms onset to the date of pulmonary tuberculosis diagnosis confirmed
immediately after asking the medical history and collecting the result of TB diagnosis
The correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
We collect the classification and the quality of the first-visit-institution of diagnosis confirmed patients by asking the past medical histories. According to the evidence of duration from symptoms onset to pulmonary TB diagnosis confirmed, use logistic correlation to find the relation between the classification of the first-visit-institution and the diagnosis delay.
immediately after asking the medical history and collecting the result of TB diagnosis

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
According to the patients' health-seeking pathways, calculate the test coverage rates including anti fast bacteria smear, tuberculosis culture, and GeneXpert in different clinical institutions. The test coverage rates is acquired by recording the laboratory test reports in medical systems or paper version from patients.
immediately after asking the medical history and collecting the result of TB diagnosis
The correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
We collect the fluoroquinolones use evidence of each patients in different clinical institutions by asking the past medical histories and reviewing paper reports from patients as well as medical system. Then use logistic correlation to find the relation between the fluoroquinolones use history and the diagnosis delay of the pulmonary tuberculosis.
immediately after asking the medical history and collecting the result of TB diagnosis
The sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
Calculating the distribution of patients' sociodemographic characteristics and correlation between results above and pulmonary tuberculosis diagnosis delay. Patients' sociodemographic characteristics includes: age, sex, marriage status, nation, occupation, education status, annual family income per capita, underlying disease such as diabetes, habits of smoking and habits of drinking alcohol.
immediately after asking the medical history and collecting the result of TB diagnosis
The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.
Time Frame: immediately after asking the medical history and collecting the result of TB diagnosis
According to the past medical history of each pulmonary tuberculosis diagnosis confirmed patients, we collect their onset symptoms and calculate the rate respectively. Then use logistic correlation to find the relation between the onset symptoms and the diagnosis delay of the pulmonary tuberculosis.
immediately after asking the medical history and collecting the result of TB diagnosis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wenhong Zhang, PHD, Huashan Hospita

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2019

Primary Completion (Actual)

November 2, 2019

Study Completion (Actual)

January 10, 2020

Study Registration Dates

First Submitted

June 14, 2020

First Submitted That Met QC Criteria

June 14, 2020

First Posted (Actual)

June 17, 2020

Study Record Updates

Last Update Posted (Actual)

June 17, 2020

Last Update Submitted That Met QC Criteria

June 14, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We would like to share the study protocol and statistical analysis plan.

IPD Sharing Time Frame

The data is available currently without expiry date.

IPD Sharing Access Criteria

Please contact y_li11@fudan.edu.cn

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis; Pulmonary, Confirmed, Unspecified Means

3
Subscribe